title: Angiographic and intravascular ultrasound findings following implantation of the Endeavor zotarolimus-eluting stents in patients from the real-world clinical practice.
abstract: OBJECTIVE
  The aim of this study was to investigate the angiographic and intravascular ultrasound (IVUS) findings of the Endeavor zotarolimus-eluting stent (ZES) in patients from a "real-world" clinical practice.
  
  
  RESULTS
  From January to March 2006, 100 patients undergoing routine or emergency percutaneous intervention were prospectively enrolled at one institution. Overall, 39% of the patients were diabetics and 80.8% of lesions were type B2/C. A total of 140 lesions were successfully treated with 174 ZES, and procedural success was 98%. Mean vessel diameter was 2.69 mm and mean lesion length was 16.0 mm; at 6-month angiographic follow-up (completed in 96%), in-stent late lumen loss was 0.66 mm, and in-segment restenosis was 8.2%. Angiographic restenosis was increased among diabetics (15.5 vs. 2.6%, p=0.009), and diabetes was the only significant predictor of angiographic restenosis (OR=15.27 [95%CI 2.45-95.04], p=0.003). By IVUS (performed in 88% at 6-month), % volume obstruction was 14.4+/-13.4%, and there was no late acquired incomplete stent apposition (ISA). At 1-year, overall MACE rate was 6%, including 5 TLRs (4% of patients), with no occurrence of stent thrombosis.
  
  
  CONCLUSIONS
  In this prospective "real-world" experience, the ZES demonstrated favourable angiographic and IVUS results in complex patients, with overall in-stent late lumen loss of 0.66 mm, and absence of late acquired ISA. At 1-year, there were no safety concerns including absence of death and stent thrombosis.
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. fferes@lee.dante.br
authors.forename: Fausto
authors.initials: F
authors.lastname: Feres
authors.forename: Pedro B
authors.initials: PB
authors.lastname: Andrade
authors.forename: Ricardo A
authors.initials: RA
authors.lastname: Costa
authors.forename: J
authors.initials: J
authors.lastname: de Ribamar Costa
authors.forename: Alexandre
authors.initials: A
authors.lastname: Abizaid
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Staico
authors.forename: Luiz F
authors.initials: LF
authors.lastname: Tanajura
authors.forename: Dimytri
authors.initials: D
authors.lastname: Siqueira
authors.forename: Julio P
authors.initials: JP
authors.lastname: Maia
authors.forename: Leandro
authors.initials: L
authors.lastname: Lasave
authors.forename: Amanda G M R
authors.initials: AG
authors.lastname: Sousa
authors.forename: J Eduardo
authors.initials: JE
authors.lastname: Sousa
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D002317:Cardiovascular Agents; C489443:zotarolimus; D020123:Sirolimus